Prophylactic Surgery and Inherited Cancer Predisposition

  • Kevin S. Hughes
  • Moshe Z. Papa
  • Timothy Whitney
  • Robert McLellan


The purpose of this chapter will be to discuss the role of prophylactic oophorectomy and prophylactic mastectomy in the management of patients with hereditary breast and ovarian cancer syndrome. The approach described here can serve as a template in reviewing the efficacy of prophylactic surgery for other hereditary cancer syndromes.


Ovarian Cancer BRCA2 Mutation Breast Reconstruction Prophylactic Mastectomy Prophylactic Surgery 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Easton DF, Ford D, Bishop DT: Breast and ovarian cancer incidence in BRCA1-mutation carriers. Am J Hum Genet 56:265–71, 1995PubMedGoogle Scholar
  2. 2.
    Ford D, Easton DF, Bishop DT, et al: Risks of cancer in BRCAl-mutation carriers. Lancet 343:692–695, 1994PubMedCrossRefGoogle Scholar
  3. 3.
    Ford D, Easton DF: The genetics of breast and ovarian cancer. Br J Cancer 72:805–812, 1995PubMedCrossRefGoogle Scholar
  4. 4.
    Easton DF, Bishop DT, Ford D, et al: Genetic linkage analysis in familial breast and ovarian cancer. Am J Hum Genet 52:678–701, 1993PubMedGoogle Scholar
  5. 5.
    Burke W, Daly M, Garber J, et al: Recommendations for follow-up care of individuals with an inherited predisposition to cancer. BRCA1 and BRCA2. JAMA 277:997–1003, 1997PubMedCrossRefGoogle Scholar
  6. 6.
    Struewing JP, Hartge P, Wacholder S, et al: The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336:1401–1408, 1997PubMedCrossRefGoogle Scholar
  7. 7.
    Fiorica JV, Roberts WS: Screening for ovarian cancer. Cancer Control 3:120–129, 1996PubMedGoogle Scholar
  8. 8.
    Hankinson SE, Colditz, GA, Hunter JJ, et al: A quantitative assessment of oral contraceptive use and risk of ovarian cancer. Obstet Gynecol 80:708, 1992PubMedGoogle Scholar
  9. 9.
    Weber AM, Hewett WJ, Gajewski WH, et al: Serous carcinoma of the peritoneum after oophorectomy. Obstetrics and Gynecology 80:(3) Part 2, Sept, 1992Google Scholar
  10. 10.
    Struewing JP, Tucker MA, Lynch HT, et al: Prophylactic oophorectomy in inherited breast/ovarian cancer families. J Natl Cancer Inst Monogr 17:33–35, 1995PubMedGoogle Scholar
  11. 11.
    Iselius L, Wilking N: Screening for familial cancer, in Weber W, Mulvihill JJ, Narod S (Eds): Familial Cancer Management. CRC Press, New York, pp 75–76Google Scholar
  12. 12.
    National Institutes of Health Consensus Development Conference Statement: Breast Cancer Screening for Women Ages 40–49, January 21–23, 1997. National Institutes of Health Consensus Development Panel. J Natl Cancer Inst 89(14):1015–26, 1997CrossRefGoogle Scholar
  13. 13.
    Landis SH, Murray T, Bolden S, et al: Cancer statistics, 1998. CA Cancer J Clin 48:6–29, 1998PubMedCrossRefGoogle Scholar
  14. 14.
    Spratt JS, Meyer JS, Spratt JA. Rates of growth of human solid neoplasms: Part I. Journal of Surgical Oncology 60:137–146, 1995PubMedCrossRefGoogle Scholar
  15. 15.
    Spratt JS, Meyer JS, Spratt JA. Rates of growth of human neoplasms: Part II. Journal of Surgical Oncology 61:68–83, 1996PubMedCrossRefGoogle Scholar
  16. 16.
    Personal communication Barbara SmithGoogle Scholar
  17. 17.
    Foulkes WD, Wong N, Brunet JS, et al: Germ-line mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer. Clinical Cancer Research 3:2465–2469, 1997PubMedGoogle Scholar
  18. 18.
    Verhoog LC, Brekelmans CTM, Seynaeve C, et al: Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 351:316–321, 1998PubMedCrossRefGoogle Scholar
  19. 19.
    Johannson OT, Ranstam J, Borg A, et al: Survival of BRCA1 breast and ovarian cancer patients: a population-based study form southern Sweden. J Clin Oncol 16:397–404, 1998Google Scholar
  20. 20.
    Crook T, Crossland S, Crompton MR, et al: p53 mutations in BRCAl-associated familial breast cancer [letter]. Lancet 350(9078):638–639,1997PubMedCrossRefGoogle Scholar
  21. 21.
    Breast cancer Linkage Consortium. Pathology of familial breast cancer: differences between breast cancers in cariers of BRCA1 and BRCA2 mutations and sporadic cases. Lancet 349:1505–1510, 1997CrossRefGoogle Scholar
  22. 22.
    Lerman C: Few BRCA1 carriers take recommended precautions. Oncology News 7, No.2:l, 1998Google Scholar
  23. 23.
    Holleb AI, Montgomery R, Farrow JH: The hazard of incomplete simple mastectomy. Surg Gynec &Obst 121:819, 1965Google Scholar
  24. 24.
    Ziegler LD, Kroll SS: Primary breast cancer after prophylactic mastectomy. Am J Clin Oncol 14:451–454, 1991PubMedGoogle Scholar
  25. 25.
    Goodnight JE Jr, Quagliana JM, Morton DL: Failure of subcutaneous mastectomy to prevent the development of breast cancer. J Surg Oncol 26:198–201, 1984PubMedCrossRefGoogle Scholar
  26. 26.
    Bowers DG, Radlauer CB: Breast cancer after prophylactic subcutaneous mastectomies and reconstruction with silastic prostheses. Plast Reconstr Surg 44:541, 1969Google Scholar
  27. 27.
    Mendez-Fernandez MA, Henly WS, Geis RC: Paget’s disease of the breast after subcutaneous mastectomy and reconstruction with a silicone prosthesis. Plast Reconstr Surg 65(5):683–685, 1980PubMedCrossRefGoogle Scholar
  28. 28.
    Eldar S, Meguid MM, Beatty JD: Cancer of the breast after prophylactic subcutaneous mastectomy. Am J Surg 148:692–693, 1984PubMedCrossRefGoogle Scholar
  29. 29.
    Jameson MB, Braatvedt GD, Probert JC, et al: Metastatic breast cancer 42 years after bilateral subcutaneous mastectomies. Clin Oncol (R Coll Radiol) 9(2):119–121, 1997CrossRefGoogle Scholar
  30. 30.
    Humphrey LJ: Subcutaneous mastectomy is not a prophylaxis against carcinoma of the breast:Opinion or knowledge? Am J Surg 145:311–321, 1983PubMedCrossRefGoogle Scholar
  31. 31.
    Pennisi VR, Capozi A: Subcutaneous mastectomy data: A final statistical analysis of 1500 patients. Aesth Plast Surg 13:15–21, 1989CrossRefGoogle Scholar
  32. 32.
    Woods JE, Meland NB: Conservative management in full thickness nipple-areolar necrosis after subcutaneous mastectomy. Plastic and reconstructive Surgery 84:258–266,1989PubMedCrossRefGoogle Scholar
  33. 33.
    Slade C, Lawrence: Subcutaneous mastectomy; Acute complications and long-term follow-up. Plastic and Reconstructive Surgery 73(l):84–88, 1984PubMedCrossRefGoogle Scholar
  34. 34.
    Fredericks S: A 10 year experience with subcutaneous mastectomy. Clin Plast Surg 2:347–357, 1975PubMedGoogle Scholar
  35. 35.
    Amaaki T, Yasumura K, Kami T, et al: Prophylactic subcutaneous total glandectomy for mammary cystic disease, with immediate primary breast reconstruction. Ann Plast Surg 3:420–424, 1979PubMedCrossRefGoogle Scholar
  36. 36.
    Hartmann L, Jenkins R, Schaid D, et al: Prophylactic mastectomy (PM): Preliminary retrospective cohort analysis. Proc Of the Am Assoc for Cancer Research 38:168, 1997Google Scholar
  37. 37.
    Mackarem G, Roche CA, Silverman ML, Hughes KS: Brief clinical report: The development of new,primary non-invasive carcinoma of the breast 29 years after bilateral radical mastectomy. The Breast Journal (in press)Google Scholar
  38. 38.
    Gabriel SE, Woods JE, O’Fallon WM, et al: Complications leading to surgery after breast implantation, New Eng Jour Med 336:677–682, 1997CrossRefGoogle Scholar
  39. 39.
    Bostwick J: Breast reconstruction following mastectomy. CA Cancer J Clin 45:289–304, 1995PubMedCrossRefGoogle Scholar
  40. 40.
    Slade CL: Subcutaneous mastectomy: Acute complications and long term follow-up. Plast Reconstr Surg 73:84–88, 1984PubMedCrossRefGoogle Scholar
  41. 41.
    Horton CE, Dascombe WH: Total mastectomy: indications and techniques. Clin Plast Surg 15:677–687, 1988PubMedGoogle Scholar
  42. 42.
    Jarrett JR: Prophylactic mastectomy, in Marsh JL, B.C. Decker BC (ed): Current Therapy in Plastic and Reconstructive Surgery, Toronto, pp 64–70, 1989Google Scholar
  43. 43.
    Jarrett JR, Cutler, RG, Teal DF: Aesthetic refinements in prophylactic subcutaneous mastectomy with submuscular reconstruction. Plast Reconstr Surg 69:625–631, 1982Google Scholar
  44. 44.
    Bostwick J, Jones G: Why I choose autogenous tissue in breast reconstruction. Clin Plast Surg 21:165–175, 1994PubMedGoogle Scholar
  45. 45.
    Elliott LF: Options for donor sites for autogenous tissue breast reconstruction. Clin Plast Surg 21:177–189, 1994PubMedGoogle Scholar
  46. 46.
    Hartrampf CR, Scheflen M, Black PW: Breast reconstruction following mastectomy with a transverse abdominal island flap, anatomic and clinical observations. Plast Reconstr Surg 69:216, 1982PubMedCrossRefGoogle Scholar
  47. 47.
    Beasley ME: The pedicled TRAM as preference for immediate autogenous tissue breast reconstruction. Clin Plast Surg 21:191–205, 1994PubMedGoogle Scholar
  48. 48.
    Bucky LP, May JW: Synthetic mesh: Its use in abdominal wall reconstruction after the TRAM. Clin Plast Surg 21:273–277, 1994PubMedGoogle Scholar
  49. 49.
    Mizgala CL, Hartrampf CR, Bennett GK, Abdominal function after pedicled TRAM flap surgery. Clin Plast Surg 21:255–272, 1994PubMedGoogle Scholar
  50. 50.
    Schusterman MA, Kroll SS, Miller MJ, et al: The free rectus abdominis musculoral contraceptivesu-taneous flap for breast reconstruction: one centers experience with 211 consecutive cases. Ann Plast Surg 32:234–242, 1994PubMedCrossRefGoogle Scholar
  51. 51.
    Watterson PA, Bostwick J, Hester TR, et al: TRAM flap anatomy correlated with a 10 year clinical experience with 556 patients. Plast Reconstr Surg 95:1185–1193, 1995PubMedCrossRefGoogle Scholar
  52. 52.
    Leibman AJ, Stylbo TM, Bostwick J: Mammography of the postreconstruction breast. Plast Reconstr Surg 99:698–704, 1997PubMedCrossRefGoogle Scholar
  53. 53.
    Noone RB, Frazier TG, Noone GC, et al: Recurrance of breast carcinoma following immediate reconstruction: a 12 year review. Plast Reconstr Surg 93:96, 1994PubMedCrossRefGoogle Scholar
  54. 54.
    Slavin SA, Love SM, Goldwyn RM: Recurrent breast cancer following immediate reconstruction with myoral contraceptivesutaneous flaps. Plast Reconstr Surg 93:1191, 1994PubMedCrossRefGoogle Scholar
  55. 55.
    Yamamoto Y, Nohira K, Sugihara T, et al: Superiority of the microvascularly augmented flap: Analysis of 50 TRAM flaps for breast reconstruction. Plast Reconstr Surg 97:79–83, 1996PubMedCrossRefGoogle Scholar
  56. 56.
    Grotting JC, Urist MM, Maddox WA, et al: Conventional TRAM flap versus free microsurgical TRAM flap for immediate breast reconstruction. Plast Reconstr Surg 83:828, 1989PubMedCrossRefGoogle Scholar
  57. 57.
    Banic A, Boeckx W, Greulich M, et al: Late results of breast reconstruction with free TRAM flaps: a prospective multicenter study. Plast Reconstr Surg 95:1195–1204, 1995PubMedCrossRefGoogle Scholar
  58. 58.
    Kroll SS: Invited discussion, re: Banic, et. al., Plast Reconstr Surg 95:1205–1206, 1995CrossRefGoogle Scholar
  59. 59.
    Shaw WW: Invited discussion, re: Shusterman, et al., Ann Plast Surg 32:241–242, 1994Google Scholar
  60. 60.
    Gross TP, Schlesselman JJ: The estimated effect of oral contraceptive use on the cumulative risk of epithelial ovarian cancer. Obstet Gynecol 83:419, 1994PubMedGoogle Scholar
  61. 61.
    Stadel RW, Rubin PA, Webster LA, et al: Oral contraceptives and breast cancer in young women. Lancet 2(8462):970–973, 1985PubMedCrossRefGoogle Scholar
  62. 62.
    Hankinson SE, Colditz GA, Hunter JJ, et al: A quantitative assessment of oral contraceptive use and risk of ovarian cancer. Obstet Gynecol 80:708, 1992PubMedGoogle Scholar
  63. 63.
    Jacobs I, Bast R: The CA125 associated antigen: A review of the literature. Hum Reprod 4:1–12, 1989PubMedCrossRefGoogle Scholar
  64. 64.
    Carlson KJ, Skates SJ, et al: Screening for ovarian cancer. Ann Intern Med 121:124–132, 1994PubMedGoogle Scholar
  65. 65.
    DePriest PD, van Nagell JR, Gallion H, et al: Ovarian cancer screening in symptomatic post-menopausal women. Gynecol Oncol 51:205, 1993PubMedCrossRefGoogle Scholar
  66. 66.
    Struewing JP, Watson P, Easton DF, Ponder BAJ, Lynch HT, Tucher MA. Prophylactic oophorectomy in inherited breast/ovarian cancer families. J Natl Cancer I Monographs 17:33–35, 1995Google Scholar
  67. 67.
    Weber AM, Hewett WJ, Gajewski WH, Curry SL: Serous carcinoma of the peritoneum after oophorectomy. Obstetrics and Gynecology 80:(3) Part 2, 1992Google Scholar
  68. 68.
    American College of Obstetricians and Gynecologists. Prophylactic Oophorectomy. ACOG Criteria Set number 2. Washington, D.C.: ACOG, 1994Google Scholar
  69. 69.
    Colditz GA, Stampfor MJ, Willett WC, et al: Prospective study of estrogen replacement therapy and risk of breast cancer in postmenopausal women. JAMA 264:2648–2653, 1990PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1999

Authors and Affiliations

  • Kevin S. Hughes
    • 1
    • 2
  • Moshe Z. Papa
    • 1
    • 2
  • Timothy Whitney
    • 1
    • 2
  • Robert McLellan
    • 1
    • 2
  1. 1.The Chaim Sheba Medical CenterSackler School of Medicine Tel Aviv UniversityTel HashomerIsrael
  2. 2.The Risk Assessment ClinicThe Lahey ClinicPeabodyUSA

Personalised recommendations